Clement Elechi, MD
Payments from drug & device makers
Across 156 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$752
- Novartis$196
- EMD Serono, Inc.$165
- Teva Pharmaceuticals USA, Inc.$158
- UCB, Inc.$121
- AstraZeneca$119
- plus $877 from 23 others
What the payments were for
- Food & beverage$2,11288%
- Education$27712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $752 |
| Novartis | 11 | $196 |
| EMD Serono, Inc. | 10 | $165 |
| Teva Pharmaceuticals USA, Inc. | 5 | $158 |
| UCB, Inc. | 5 | $121 |
| AstraZeneca | 2 | $119 |
| Biogen | 4 | $100 |
| Genentech USA, Inc. | 5 | $90 |
| Pfizer | 4 | $84 |
| GE HealthCare | 5 | $63 |
| Tactile Systems Technology Inc | 1 | $56 |
| Hospira, Inc. | 3 | $54 |
| Lilly USA, LLC | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Harmony Biosciences LLC | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Argenx US, Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Amgen | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Resmed Corp | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $11 |
How this compares
$2,388 in reported general payments places this provider in the 55th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 28 | $266,906 |
| TecfideraDimethyl Fumarate | 26 | $235,489 |
| BetaseronInterferon Beta-1b | 19 | $172,804 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $142,625 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $134,426 |
| VumerityDiroximel Fumarate | 14 | $122,245 |
| Plegridy PenPeginterferon Beta-1a | 14 | $115,722 |
| Kesimpta PenOfatumumab | 13 | $110,409 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 26 | $103,535 |
| LamictalLamotrigine | 14 | $91,426 |
| Nurtec OdtRimegepant Sulfate | 51 | $75,867 |
| Dimethyl Fumarate | 49 | $74,687 |
| CopaxoneGlatiramer Acetate | 12 | $70,334 |
| UbrelvyUbrogepant | 49 | $58,655 |
| GlatopaGlatiramer Acetate | 26 | $54,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity | $100 | $357,73440 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $158 | $337,24040 claims |
| PfizerOctagam, Nurtec Odt, Dilantin | $84 | $191,049104 claims |
| AbbVieUbrelvy, Qulipta | $752 | $94,67781 claims |
| UCB, Inc.Briviact | $121 | $16,21911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 474 neurology providers in Virginia.
Other neurology in Salem
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
- Rahul DaveFairfax$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.